Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Pfizer

Status: Completed

Conditions: Candidiasis

Treatments: Drug: anidulafungin

Study type: Observational

Funder types: Industry

Identifiers

NCT01202253

A8851028

Details and patient eligibility

About

The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.

Full description

All subjects that have been treated with Anidulafungin according to its licence during the period of July 2009 and September 2010 will be included.

Enrollment: 50 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who have been prescribed anidulafungin between 1st July 2009 and 30th September 2010.

Patients admitted to specialist liver unit wards and the Liver Intensive Therapy Unit during this period

Exclusion criteria

• Patients who participated in any interventional clinical trial during this episode of sepsis.

Patients who received anidulafungin for infection prophylaxis

Trial design

50 participants in 1 patient group

Anidulafungin

Treatment:

Drug: anidulafungin